BioNTech and Pfizer said on Wednesday a three-time course of them Vaccines against covid-19 was able to disable the new one Omicron variant in a lab trial, and they could deliver an Omicron-based vaccine by March 2022 if needed.
In the first official statement from vaccine manufacturers about the potential effectiveness of the shot against Omicron, BioNTech and Pfizer said that two doses of the vaccine resulted in significantly lower levels of neutralizing antibodies but the vaccine dose Their third increased the amount of neutralizing antibodies to 25.
Blood taken from people who received their third booster one month ago neutralized the Omicron variant as effectively as blood after two injections against the original virus first identified in China. Country.
“Ensuring as many people as possible are fully immunized with the first two doses and booster shots remains the best course of action to prevent the spread of COVID-19,” Pfizer boss Albert Bourla said in a statement. declare.
While the need is still unclear, the companies say they will continue their efforts to bring the Omicron-specific COVID-19 vaccine to market, which they kicked off when the vaccine line-up began. for the first time caused global concern among scientists on November 25.
A projected output of 4 billion doses of the Comirnaty vaccine in 2022 was not expected to change if an adapted vaccine was required, they added.
The findings are fully consistent with a preliminary study published by researchers at the African Health Research Institute in South Africa on Tuesday, which said that Omicron may partially avoid protection from two dose of the Pfizer/BioNTech vaccine, also suggests that the third shot may be helpful against infection.
Mixing and matching COVID-19 vaccine boosters prove effective: study
A laboratory analysis at the university hospital Frankfurt, Germany, however found an antibody response down to Omicron even after three injections.
The US-German vaccine partners also struck an upbeat tone about the prospect that their shot protects against any serious illness from Omicron, although the lab data did not yield new insights. about that.
Much of the surface structure on the Omicron spike protein targeted by T cells, which normally appear after vaccination, is unaffected by the Omicron mutations, they say.
They added: “Companies believe that people who get vaccinated can still be protected against serious forms of the disease.
T cells are the second pillar of an immune response, along with antibodies, and are thought to prevent serious disease by attacking infected human cells.
https://globalnews.ca/news/8433176/booster-dose-pfizers-covid-19-vaccine-neutralizes-omicron-variant/ Company says booster dose of Pfizer’s COVID-19 vaccine neutralizes Omicron variant